YTE-engineered antibodies: From neonatal Fc receptor binding mechanisms to next-generation therapeutics

Background on monoclonal antibodies (mAbs)

mAbs have revolutionized modern medicine, becoming one of the most successful therapeutic classes in the last three decades.^[1,2] Their high target specificity and generally favorable safety profile have enabled applications across oncology, infectious diseases, and autoimmune disorders.^[3] By 2024, over 100 therapeutic mAbs had received regulatory approval worldwide, with many more in clinical development.^[4] Structurally, immunoglobulin G (IgG) contains two antigen-binding Fab regions and one Fc region. While the Fab arms mediate antigen recognition and neutralization, the Fc domain interacts with Fc receptors and complement proteins, governing immune effector functions and pharmacokinetics (PKs).^[5,6] Despite these advantages, conventional IgG1 antibodies typically have a serum half-life of only 20–21 days in humans.^[7,8] necessitating repeated dosing.

Why half-life matters in therapeutics

Half-life is a critical determinant of clinical utility, dosing frequency, and patient compliance. A longer serum half-life reduces injection frequency, improving adherence in chronic diseases such as rheumatoid arthritis and inflammatory bowel disease.^[9,10] In infectious disease prevention, extended half-life allows seasonal or long-term protection from viral pathogens such as respiratory syncytial virus (RSV), human immunodeficiency virus (HIV), and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).^[11,12] Similarly, in oncology, prolonged half-life maintains sustained therapeutic pressure on tumor cells.^[13] From a healthcare perspective, long-acting antibodies reduce production costs, hospital visits, and treatment burden.^[14]

Role of FcRn in antibody recycling

The neonatal Fc receptor (FcRn) plays a pivotal role in prolonging IgG persistence in circulation. FcRn binds to the Fc region of IgG at acidic pH within endosomes, rescues IgG from lysosomal degradation, and recycles it back into plasma upon dissociation at neutral pH.^[15] This pH-dependent salvage pathway explains the relatively long half-life of IgG compared with most plasma proteins.^[16] Beyond drug PKs, FcRn also regulates maternal IgG transport across the placenta, contributing to neonatal immunity.^[17]

Need for Fc engineering: Introducing tyrosine-threonineglutamic acid (YTE) mutation

Although wild-type IgG benefits from FcRn-mediated recycling, its half-life is often insufficient for long-term prophylaxis or durable therapies. Fc engineering has therefore emerged as a strategy to optimize FcRn interactions and extend antibody persistence.^[18] Among engineered Fc variants, the triple substitution M252Y/S254T/T256E (YTE) at the CH2–CH3 interface stands out as one of the most widely studied and clinically validated approaches.^[19] This substitution significantly enhances FcRn binding affinity at acidic pH while allowing dissociation at neutral pH, thereby improving antibody recycling and reducing lysosomal degradation.^[20] Preclinical studies in non-human primates confirmed up to a fourfold increase in half-life,^[21] and clinical studies with motavizumab-YTE demonstrated unprecedented extension of IgG persistence in humans.^[22] These findings established YTE as a benchmark Fc modification for next-generation antibody therapeutics.

Location of M252, S254, and T256 in the Fc region

(Met252–Ser254–Thr256), a short amino acid sequence located at the lower hinge/CH2–CH3 junction that plays a crucial role in FcRn. The Fc portion of human IgG comprises the CH2 and CH3 constant domains of the heavy chain, which together form the FcRn-binding interface. Within this interface lies the methionine-serine-threonine (MST) motif recognition.^[23,24] Structural studies using crystallography and molecular modelling revealed that these residues face the FcRn binding pocket and directly interact with receptor residues under acidic conditions.^[25] Even though multiple residues across the Fc contribute to FcRn binding, the MST triplet provides a key anchoring site, and mutations here directly alter the stability and affinity of Fc–FcRn complexes.^[26]

Importantly, the overall IgG architecture and the positions of the CH2 and CH3 domains relative to FcRn are illustrated in Figure 1, which highlights the Fab region, Fc region, and the specific residues (M252, S254, T256) that are substituted in the YTE mutation.

Close

Figure 1:

Structure of an immunoglobulin G antibody and regions relevant to YTE mutation. Schematic representation of a monoclonal antibody showing the Fab region (antigen-binding fragment) and Fc region (fragment crystallizable). The constant domains (CH2, CH3) within the Fc region are highlighted, where the YTE substitution (M252Y/S254T/T256E) is introduced to enhance binding to the neonatal Fc receptor and extend antibody half-life.

Export to PPT

How substitution alters FcRn interactions

The YTE mutation replaces methionine (M252) with tyrosine, serine (S254) with threonine, and threonine (T256) with glutamic acid. Each substitution contributes distinct structural and electrostatic changes:

• M252Y introduces a bulky aromatic side chain that enables additional hydrogen bonding and π-stacking interactions with FcRn residues, while enhancing van der Waals contacts^[27]

• S254T adds a methyl group, improving hydrophobic packing and stabilizing the local backbone conformation near the FcRn binding loop^[28]

• T256E introduces a negatively charged side chain, creating stronger electrostatic interactions with positively charged residues on FcRn at acidic pH, but releasing efficiently at neutral pH.^[29]

Quantitative FcRn binding and structural consequences

Biophysical studies consistently demonstrate that the YTE triple substitution markedly enhances FcRn binding at acidic endosomal pH (~6.0), typically by ~8–12-fold compared with wild-type IgG1, while maintaining weak binding at physiological pH 7.4.^[30,31] In contrast, leusine-serine (LS) substitutions generally produce more modest affinity increases of approximately 3–5-fold.^[32,33] These quantitative differences arise from localized structural effects at the CH2– CH3 junction: M252Y introduces an aromatic side chain contributing to enhanced π-stacking and hydrogen-bonding potential; S254T improves local packing and backbone stabilization; and T256E contributes a negatively charged residue capable of forming favorable electrostatic interactions with protonated FcRn residues under acidic conditions.^[34,35] Collectively, these alterations stabilize the Fc–FcRn complex within the acidic endosome while preserving low-affinity interactions at neutral pH, thereby supporting efficient recycling without increased surface retention.^[36]

Collectively, these substitutions enhance FcRn binding affinity at acidic pH by nearly 10-fold, while maintaining dissociation at neutral pH.^[37] This balance ensures that YTE antibodies undergo efficient endosomal salvage without being trapped intracellularly, resulting in extended serum half-life.^[38]

Acidic versus neutral pH binding

FcRn-mediated IgG recycling depends on pH-sensitive interactions between the Fc domain and FcRn. In acidic endosomes (pH ~6.0), protonation of histidine residues within the Fc domain promotes hydrogen bonding and salt-bridge formation with acidic residues on FcRn, enabling strong binding. YTE substitutions enhance this process by creating additional stabilizing interactions: tyrosine at 252 provides aromatic stacking, threonine at 254 improves hydrophobic packing, and glutamic acid at 256 strengthens electrostatic complementarity with FcRn.^[39,40] At neutral extracellular pH (~7.4), these stabilizing interactions weaken, allowing IgG release back into circulation. Thus, the YTE variant improves endosomal binding while preserving physiological dissociation, which is critical for antibody homeostasis.^[41]

Why enhanced acidic binding fails to cause intracellular trapping

A key requirement for the clinical success of YTE is the retention of pH-dependent receptor release, with enhanced binding at pH ~6.0 but not pH 7.4, thus allowing drug release at the cell surface.^[1] A rationale for this mechanism rests with the introduced residues, which form electrostatic and aromatic interactions that are stabilized by the protonation states present specifically at low pH but not at neutral pH, thereby facilitating release.^[42] Moreover, cell-based recycling assays have also revealed preserved exocytosis rather than intracellular sequestration of YTE molecules, in line with the PK profile of remarkable circulating persistence.^[43] The difference versus LS likely reflects the nature and location of the substitutions: YTE’s combination of aromatic packing (Y) and a pH-sensitive charged residue (E) preferentially increases the pH dependence of binding, yielding large boosts at acidic pH while keeping neutral-pH interactions weak. LS substitutions (M428L/N434S) produce more modest affinity gains and may have different influences on adjacent Fc regions and Fc gamma receptor (FcγR) contacts.^[44]

FcRn recycling pathway

After antibodies enter cells by fluid-phase pinocytosis, FcRn binding determines their fate. Wild-type IgG binds moderately at acidic pH, with a portion escaping to lysosomal degradation. In contrast, YTE-modified antibodies form a much more stable Fc–FcRn complex at acidic pH, reducing lysosomal targeting and directing them into recycling endosomes.^[45] These vesicles then fuse with the plasma membrane, where the neutral extracellular pH promotes antibody release back into circulation. This cycle can repeat multiple times, leading to significantly prolonged persistence of YTE antibodies in vivo.^[46] The enhanced salvage and recycling efficiency of YTE-modified antibodies is summarized schematically in Figure 2.

Close

Figure 2:

Neonatal Fc receptor (FcRn)-mediated recycling of YTE-engineered antibodies interpretive legend. Schematic of the endosomal salvage pathway. YTE substitutions increase Fc–FcRn affinity at endosomal pH (~6.0), increasing residence in recycling endosomes and reducing lysosomal degradation; on the cell surface (pH ~7.4), weakened interactions allow efficient antibody release. Clinically, this mechanism translates to prolonged systemic exposure (3–4× half-life extension). The schematic emphasizes pH-dependence rather than absolute intracellular concentrations; empirical confirmation using cell-based recycling assays and in vivo pharmacokinetics is necessary for each antibody backbone.

Export to PPT

Comparison with wild-type IgG

Unmodified human IgG1 has a half-life of ~20–21 days, but only moderate FcRn binding at acidic pH.^[47] As a result, a considerable fraction of IgG is degraded after uptake. YTE-engineered antibodies improve FcRn binding affinity at pH 6.0 by up to 10-fold, rescuing more antibodies from degradation.^[48] Importantly, this improvement does not significantly enhance binding at neutral pH, preventing intracellular trapping. In primates, YTE variants extended IgG half-life 3–4-fold compared with wild-type antibodies.^[49] Clinical trials with motavizumab-YTE and nirsevimab confirmed these findings, showing human half-lives of 60–100 days.^[50] These comparative results are illustrated in Figure 2, which contrasts the recycling pathways of wild-type versus YTE-modified IgG.

Non-human primate studies

Initial validation of the YTE mutation came from studies in cynomolgus monkeys, a preferred model due to their FcRn biology being similar to humans.^[51] Antibodies engineered with the M252Y/S254T/T256E substitutions demonstrated significantly longer persistence in circulation compared to wild-type IgG1.^[52] In independent studies, YTE-modified antibodies achieved serum half-lives of approximately 60–80 days, representing a 3–4-fold increase over the ~20-day half-life of unmodified IgG.^[53] Importantly, these improvements did not compromise antigen-binding activity, confirming that YTE substitutions specifically altered FcRn-mediated recycling without affecting Fab function.

PK data

PK analyses further demonstrated that YTE antibodies improved not only half-life but also key parameters such as area under the curve and mean residence time.^[54] Enhanced FcRn binding at acidic pH increased recycling efficiency, reduced lysosomal degradation, and allowed for higher steady-state serum concentrations.^[55] These findings suggest that YTE engineering is framework-independent and can be applied across multiple antibody backbones, making it a versatile strategy for therapeutic optimization.^[56]

RSV neutralization in animal models

Motavizumab, a high-affinity anti-RSV mAb, was modified with YTE substitutions to test whether half-life extension improved antiviral efficacy. In cotton rats and primates challenged with RSV, motavizumab-YTE showed prolonged protective concentrations and significantly reduced viral loads in both the lungs and upper airways compared to unmodified motavizumab. Protective levels were maintained well beyond the typical half-life of wild-type IgG, highlighting the functional benefit of Fc engineering in enhancing antiviral durability.^[57]

Clinical evidence and objective outcomes

Fc-engineered antibodies with YTE-swapped antibodies have been assessed in their potential for clinical use. To maintain impartiality and clear transparency, we have summarized below some of the essential information regarding trial identifiers, phases, study participants, endpoints, safety concerns, and outcomes. When registry identifiers or study size are not described in publications, this is made clear. The key clinical outcomes of YTE-engineered antibodies are summarized in Table 1.

Motavizumab-YTE (respiratory syncytial virus)

Motavizumab-YTE was tested in a Phase 1 randomized clinical trial^[58] among healthy adult participants (n = 48). PK analysis revealed a mean half-life of ~70-100 days, which reflected a ~3-5-fold extension relative to the wild-type IgG control groups. Although there were no serious adverse events due to the antibody, the trial cannot assess the issue of delayed immunogenicity owing to the small number of participants. The developmental status for the antibody was terminated, which also meant that it is not approved for use as a treatment.^[58]

Nirsevimab (RSV prophylaxis in infants)

Nirsevimab (MEDI8897), targeting RSV, has completed both Phase 2b and Phase 3 trials. In a Phase 2b trial (NCT02878330; pre-term infants; n = 200),^[59] a significant decrease in medically attended RSV infection and a prolonged half-life of approximately 80–120 days for nirsevimab were observed.^[60]

This finding was reaffirmed in a Phase 3 clinical study (NCT03979313; ≥1500 infants).^[61] The observed adverse reactions made no unexpected claims for infant morbidity and thus showed no unexpected safety concerns associated with nirsevimab. This product has marketing approval for RSV prevention for infants.^[62]

Vaccine Research Center 01 (VRC01)-YTE (HIV-1 neutralizing antibody)

VRC01-YTE, a YTE-engineered broad neutralizer specific for HIV-1, has been tested in early clinical trials termed Phase 1 (unknown identifier) in human adult volunteers (unknown) for a duration not specified. The attempt of YTE-engineered modifications was to maximize systemic exposure as well as the levels of neutralizing sera. While PK information has been published showing extended serum levels as compared with VRC01 unengineered counterparts, population characteristics are not well captured in the literature to a satisfactory degree.

Anti-SARS-CoV-2-YTE

Clinical trials of YTE-modified antibodies against SARSCoV-2 implemented an assessment of these antibodies during the early stages of both healthy and SARS-CoV-2-infected individuals. Regarding one of the antibodies described, there is no ClinicalTrials.gov identifier number given within the initial findings, and certain characteristics, such as its stage and population size, are not described. Consequently, data regarding half-life extension and neutralizing ability, as well as safety indications, could not be ascertained independently. Furthermore, there is no update on regulatory findings for YTE-modified antibodies against SARS-CoV-2.

LS (M428L/N434S), QL, and others

In addition to YTE, several other Fc substitutions have been designed to enhance FcRn binding and prolong antibody persistence. The LS mutation (M428L/N434S) increases FcRn affinity at acidic pH and has been incorporated into several clinical antibodies, including VRC01-LS for HIV prevention and ravulizumab, a complement inhibitor.^[63] The QL variant (T307Q/E380A/N434A) has also demonstrated FcRn binding improvements and extended serum half-life in preclinical models. Other engineered Fc variants, such as REW,^[64] continue to be explored for optimized PKs. While these approaches are effective, YTE generally produces greater half-life extensions, often exceeding those of LS and QL variants.^[60]

Direct comparisons in FcRn binding and PKs

Head-to-head analyses show that YTE antibodies achieve up to a 10-fold increase in FcRn affinity at pH 6.0, compared to a 3–5-fold increase for LS mutants.^[65] Correspondingly, YTE antibodies extended half-life 3–4 times in humans, while LS typically yielded 2–3 times extension.^[66] Although LS is considered to preserve Fcγ receptor binding and effector functions better, YTE remains the most potent half-life extension strategy validated in human trials.^[67]

Comparative summary

These differences are summarized in Table 2, which highlights FcRn affinity changes, half-life extensions, and representative clinical applications of YTE, LS, and QL substitutions. Such comparisons emphasize that while multiple Fc engineering strategies exist, YTE serves as the benchmark for maximal half-life extension.

Mechanistic comparison (YTE vs. LS vs. QL)

YTE substitutions are concentrated at the CH2–CH3 junction (M252Y/S254T/T256E), directly shaping the FcRn contact surface and markedly increasing pH-dependent electrostatic and aromatic interactions.^[68] In contrast, LS and QL variants alter residues located nearer to the CH3 domain (e.g., M428L/N434S), producing more modest increases in FcRn affinity while generally imposing less perturbation on CH2-associated structural elements implicated in FcγR engagement.^[69] Practically, YTE tends to yield larger half-life extension but may carry a greater theoretical likelihood for subtle FcγR or effector-function modulation in certain antibody backbones. In contrast, LS variants often achieve moderate half-life gains with better preservation of canonical effector profiles.^[70] These mechanistic distinctions reinforce the need for antibody-specific evaluation of FcγR and complement interactions, rather than assuming a universally superior Fc modification strategy.^[71]

Prolonged half-life and reduced dosing frequency

The most significant advantage of the YTE substitution is the 3–4-fold extension of IgG half-life, which translates directly into less frequent dosing schedules.^[72] For chronic diseases such as autoimmune disorders, this reduction minimizes treatment burden and improves patient adherence. In infectious disease prophylaxis, YTE-based antibodies such as nirsevimab provide season-long protection with a single injection, eliminating the need for monthly dosing regimens.^[73]

Improved patient compliance and cost-effectiveness

An extended half-life reduces the frequency of hospital visits and overall drug administration, improving patient compliance and lowering healthcare costs.^[74] For biologics that are otherwise expensive to produce and administer, half-life extension strategies significantly enhance cost-effectiveness by reducing the number of doses required per year.^[75]

Broad applicability across therapeutic areas

YTE engineering is not disease-specific; it has been successfully applied to antibodies against RSV (motavizumab, nirsevimab), HIV-1 (VRC01-YTE), and SARS-CoV-2 variants.^[76] Beyond viral pathogens, FcRn optimization has been explored for antibodies in oncology and chronic inflammatory conditions.^[77] This broad applicability makes YTE engineering a versatile platform technology for next-generation antibody therapeutics.

Potential immunogenicity risks

One major concern with introducing amino acid substitutions into the Fc domain is the potential to create novel T-cell or B-cell epitopes, leading to anti-drug antibody (ADA) responses.^[78] Although clinical trials with YTE variants such as motavizumab-YTE and nirsevimab reported no significant immunogenicity issues,^[79] the possibility of long-term immune responses remains a regulatory consideration.

Altered Fc receptor interactions

Fc engineering can sometimes affect FcγR binding and complement activation, thereby altering immune effector functions such as ADCC (antibody-dependent cellular cytotoxicity) and complement-dependent cytotoxicity (CDC).^[80] Although YTE substitutions primarily act on FcRn and have not shown major adverse effects on FcγR binding,^[81] some reports suggest that changes at the CH2–CH3 interface may subtly alter effector function in certain IgG subclasses.^[82]

Impact on FcγR-mediated effector functions

YTE substitutions are primarily designed to improve FcRn binding without directly altering FcγR contact residues; however, subtle changes at the CH2–CH3 interface can, in some antibody backbones, influence Fcγ receptor engagement and downstream effector mechanisms such as ADCC or complement activation.^[83] These effects are not consistently observed across all antibodies and therefore require molecule-specific verification through in vitro FcγR binding assessments and functional assays. Importantly, available clinical and pharmacodynamic data do not demonstrate any major impairment of effector functions for approved Fc-engineered antibodies such as nirsevimab, although continued mechanistic evaluation remains important during development.^[84]

Quantitative biophysical analyses demonstrate that YTE variants enhance FcRn affinity approximately tenfold at acidic endosomal pH, with reported dissociation constant (KD) values improving from ~800–1000 nM for wild-type IgG1 to ~60–100 nM at pH 6.0, while maintaining weak binding (>1–5 μM) at physiological pH 7.4. In comparison, LS variants generally produce more modest affinity gains (~3–5-fold), with KD values around ~200– 300 nM at pH 6.0.^[85] These quantitative differences correlate with the superior FcRn recycling efficiency and extended serum half-life typically observed with YTE variants in vivo.

Clinical translation challenges

While YTE engineering has demonstrated remarkable success in infectious diseases, its widespread adoption has been somewhat limited compared to LS (M428L/N434S) variants.^[86] This is partly due to commercial strategies and partly due to concerns that overly strong FcRn binding might alter pharmacodynamics in certain therapeutic contexts.^[86] Furthermore, the balance between extended half-life and maintaining optimal effector function continues to be an active area of research in Fc engineering.^[87]

Limitations and possible risks

Although YTE substitutions reliably enhance FcRn binding and prolong serum persistence, several caveats preclude unqualified assertions of universal advantage. First, although engineered to preferentially modulate FcRn affinity, alterations at the CH2–CH3 interface can, in some antibody frameworks, subtly influence Fcγ receptor interactions and complement engagement, with potential implications for ADCC and CDC.^[88] Accordingly, each YTE-modified antibody requires empirical confirmation of preserved effector activity through FcγR binding and functional assays.

Second, prolonged systemic residence increases the likelihood of altered biodistribution and immune-complex handling; extended antibody exposure may prolong immune-complex persistence and influence Fc-mediated clearance pathways, warranting appropriate preclinical and clinical monitoring.^[89]

Third, the potential for ADA responses remains an ongoing regulatory consideration for Fc-engineered platforms. While major YTE-containing clinical programs, including motavizumab-YTE and nirsevimab, have reported generally low immunogenicity, long-term surveillance and larger real-world datasets are required.^[90]

Finally, for each clinical antibody candidate, regulatory trajectories and post-marketing safety outcomes should be documented when available; when absent, this limitation should be explicitly acknowledged.

Strengths versus risks

Next-generation Fc engineering

YTE engineering has set the benchmark for half-life extension, but Fc optimization continues to evolve. Next-generation approaches involve combinations of substitutions, such as YTE-LS hybrids, which aim to maximize FcRn affinity while preserving FcγR binding and effector functions.^[95] Structural modeling and computational design are also accelerating the discovery of novel Fc variants with tailored PK profiles.^[95]

Combination with other strategies

Fc engineering may be combined with other half-life extension platforms, such as PEGylation, albumin fusion, or bispecific antibody design.^[96] These complementary strategies could further enhance therapeutic durability and allow antibodies to be customized for specific clinical needs. The integration of Fc engineering with gene-delivered antibodies is another emerging concept, where long-acting variants like YTE could be expressed directly in patients through viral vectors, potentially enabling “single-shot” passive immunization.^[97]

Broader applications of YTE and related approaches

Beyond infectious diseases, YTE-based antibodies are being explored in oncology, chronic inflammatory diseases, and even rare genetic disorders.^[98] As antibody therapeutics expand to new indications, the demand for half-life extension technologies will grow. Lessons learned from YTE engineering will likely inform the design of future antibody platforms, guiding rational Fc modification strategies.